A Phase 2 interventional study of Atorvastatin injection in Hypercholesterolemia and Dyslipidemias, sponsored by Cumberland Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-15.
Sponsored by Cumberland Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 62nd largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2018, is one of 10 in phase 2, and was the 72nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Cumberland Pharmaceuticals has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 = Baseline daily dose of 10 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
Drug: Atorvastatin injection
Cohort 2 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
Drug: Atorvastatin injection
Cohort 3 = Baseline daily dose of 40 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
Drug: Atorvastatin injection
Cohort 4 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then SC study drug for up to 15 days
Drug: Atorvastatin injection
statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C
LDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline LDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 LDL-C not more than 125% of their baseline.
Time frame: Baseline, 15 Days
Efficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C
HDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline HDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 HDL-C not less than 75% of their baseline.
Time frame: Baseline, 15 Days
Change in Baseline LDL-C Concentration
Mean change in LDL-C (mg/dL) from baseline at Day 15
Time frame: Baseline, 15 days
Cmax IV
The maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Tmax IV
The time to maximum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
AUC 0-24
The AUC 0-24 of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
AUC Inf
The AUCinf of atorvastatin following an intravenous injection to a patient at steady-state.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
VDss
The volume of distribution at steady state of atorvastatin following an intravenous injection to a patient.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
t 1/2
The half-life of atorvastatin following an intravenous injection to a patient at a steady state.
Time frame: 3 to 7 minutes, 0.5h, 1h 2h, 4h, 6h, 8h, 24h post-dose
Enrollment occurred between 07Aug2018 and 24Feb2020. Three types of patients, categorized by statin use prior to study participation were eligible: patients taking oral atorvastatin, patients taking statins other than atorvastatin, patient not taking any statins prior to study. In Amendment 03. the fourth 80mg dose was eliminated and the 15 days IV route administration was changed to subcutaneous administration.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 14 | 14 | 2 | 10 |
| Completed | 14 | 14 | 2 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 14 | 14 | 2 | 10 |
| Completed | 13 | 14 | 2 | 10 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Inaccessible veins | 1 | 0 | 0 | 0 |
LDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline LDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 LDL-C not more than 125% of their baseline.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C | 9 | 9 | 1 | 7 |
HDL-C levels were measured prior to and at the end of the 15 day treatment period to quantify the percent baseline HDL-C at 15 days. Efficacy is defined as eleven or more subjects in a dosing cohort with a Day 15 HDL-C not less than 75% of their baseline.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Efficacy, Number of Participants With Day 15 HDL-C More Than or Equal to 75% Baseline HDL-C | 11 | 13 | 1 | 9 |
Mean change in LDL-C (mg/dL) from baseline at Day 15
| mg/dL | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Change in Baseline LDL-C Concentration | 12.36 ± 14.740 | 2.62 ± 34.844 | 27.50 ± 14.849 | 11.22 ± 13.283 |
The maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
| mg/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Atorvastatin | 284.33 ± 189.540 | 830.34 ± 1141.919 | 507.50 ± 443.456 |
| 2-Hydroxy Atorvastatin | 0.40 ± 0.87 | 1.23 ± 0.450 | 3.23 ± 1.987 |
| 4-Hydroxy Atorvastatin | 0.24 ± 0 | 0.30 ± 0.163 | 0.75 ± 0.370 |
The time to maximum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
| hours | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Atorvastatin | 0.08 (0.0 to 0.5) | 0.08 (0.0 to 0.5) | 0.15 (0.1 to 0.2) |
| 2-Hydroxy Atorvastatin | 6.00 (6.0 to 8.0) | 6.0 (2.0 to 8.0) | 5.00 (4.0 to 6.0) |
| 4-Hydroxy Atorvastatin | 0.08 (0.0 to 0.1) | 6.0 (0.0 to 8.0) | 8.0 (8.0 to 8.0) |
The AUC 0-24 of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.
| ng*hr/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Atorvastatin | 72.12 ± 31.216 | 137.04 ± 134.608 | 212.00 ± 89.095 |
| 2-Hydroxy Atorvastatin | 3.35 ± 2.603 | 16.76 ± 6.283 | 49.20 ± 26.698 |
| 4-Hydroxy Atorvastatin | NA ± NA | 5.45 ± 3.691 | 12.65 ± 5.303 |
The AUCinf of atorvastatin following an intravenous injection to a patient at steady-state.
| ng*hr/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| AUC Inf | 72.19 ± 31.196 | 167.32 ± 138.099 | 217.00 ± 89.095 |
The volume of distribution at steady state of atorvastatin following an intravenous injection to a patient.
| liter | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| VDss | 71.86 ± 81.475 | 135.53 ± 145.579 | 182.85 ± 140.219 |
The half-life of atorvastatin following an intravenous injection to a patient at a steady state.
| hours | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| t 1/2 | 4.79 ± 4.311 | 6.22 ± 1.884 | 6.38 ± 0.085 |
Collected over 15 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Cohort 2 | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Cohort 3 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 4 | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 0/14 | 0/14 | 1/2 | 0/10 |
| HeadacheNervous system disorders | 2/14 | 0/14 | 0/2 | 0/10 |
| Injection site painGeneral disorders | 0/14 | 0/14 | 0/2 | 1/10 |
| Viral infectionInfections and infestations | 0/14 | 0/14 | 0/2 | 1/10 |
| Alanine aminotransferase increasedInvestigations | 0/14 | 0/14 | 0/2 | 1/10 |
| Aspartate aminotransferase increasedInvestigations | 0/14 | 0/14 | 0/2 | 1/10 |
| Vision blurredEye disorders | 1/14 | 0/14 | 0/2 | 0/10 |
| HypersensitivityImmune system disorders | 1/14 | 0/14 | 0/2 | 0/10 |
| Lip injuryInjury, poisoning and procedural complications | 0/14 | 1/14 | 0/2 | 0/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/14 | 0/14 | 0/2 | 0/10 |
Safety Population: All subjects who received at least a partial dose of investigational medicinal product. No treated subjects were excluded from the safety population.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 44.8 ± 9.74 | 51.4 ± 8.21 | 46.0 ± 18.38 | 50.4 ± 10.47 | 48.6 ± 9.9 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 6 | 5 | 1 | 5 | 17 |
| Male | 8 | 9 | 1 | 5 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 5 | 1 | 4 | 17 |
| Not Hispanic or Latino | 7 | 9 | 1 | 6 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 6 | 0 | 4 | 15 |
| White | 9 | 8 | 2 | 5 | 24 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Prior Atorvastatin Use or Using Oral Atorvastatin(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Prior Atorvastatin Use or Using Oral Atorvastatin | 6 | 4 | 1 | 5 | 16 |
| Prior Statin Other than Atorvastatin Use | 1 | 1 | 0 | 0 | 2 |
| No Prior Statin Use | 7 | 9 | 1 | 5 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Feb 2020, 18 months.
Results were first posted in Jul 2022, 2 years 4 months after primary completion. A results delay was requested in Jan 2021.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 18 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin